Do you want to read an article? Please log in or register.
Five-Year Cumulative Cardiovascular Health and Clinical Events in Patients With Chronic Kidney Disease: The CRIC Study
Cardiovascular Risk and Diseases
Related content
Cardiovascular Risk and Diseases
The association between stress-induced hyperglycemia ratio and cardiovascular events as well as all-cause mortality in patients with chronic kidney disease and diabetic nephropathy
Cardiovasc Diabetol
Cao B, Guo Z, Li DT, Zhao LY, Wang Z, Gao YB, Wang YX
doi: 10.1186/s12933-025-02610-1
Heart, Artery and Coronary DiseasesFurther Publications
Angiographic Characteristics and Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing Impella-Supported High-Risk Percutaneous Coronary Intervention: Insights From the cVAD PROTECT III Study
Circ Cardiovasc Interv
Bharadwaj AS, Abu-Much A, Maini AS, Zhou Z, Li Y, Batchelor WB, Grines CL, Baron SJ, Redfors B, Lansky AJ, Basir MB, O'Neill WW
doi: 10.1161/CIRCINTERVENTIONS.123.013503
Cardiovascular Risk and Diseases
Risk acceleration by gout on major adverse cardiovascular events and all-cause death in patients with diabetes and chronic kidney disease
Diabetes Obes Metab
Lee DY, Moon JS, Jung I, Chung SM, Park SY, Yu JH, Seo JA, Han KD, Kim NH
doi: 10.1111/dom.16165
Heart Failure
Incidence of clinical outcomes in heart failure patients with and without advanced chronic kidney disease
ESC Heart Fail
Zahir Anjum D, Bonde AN, Fosbol E, Hartwell Garred C, Gislason G, Elmegaard M, Knigge P, Torp-Pedersen C, Andersson C, Pfeffer MA, Jhund PS, McMurray JJV, Petrie MC, Kober L, Schou M
doi: 10.1002/ehf2.14933
RECOMMENDED
Cardiovascular Risk and DiseasesFurther Publications
Carotid Plaque Score is Associated with 10-year Major Adverse Cardiovascular Events in Low-Intermediate Risk Patients Referred to a General Cardiology Community Clinic
★ 2
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Eur Heart J Cardiovasc Imaging
Matangi MF, Hétu MF, Armstrong DWJ, Shellenberger J, Brouillard D, Baker J, Johnson A, Grubic N, Willms H, Johri AM
doi: 10.1093/ehjci/jeae153
Cardiovascular Risk and Diseases
Definitions of clinical study outcome measures for cardiovascular diseases: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart)
Eur Heart J
Wilkinson C, Bhatty A, Batra G, Aktaa S, Smith AB, Dwight J, Ruciński M, Chappell S, Alfredsson J, Erlinge D, Ferreira J, Guðmundsdóttir IJ, Hrafnkelsdóttir ÞJ, Ingimarsdóttir IJ, Irs A, Jánosi A, Járai Z, Oliveira-Santos M, Popescu BA, Vasko P, Vinereanu D, Yap J, Bugiardini R, Cenko E, Nadarajah R, Sydes MR, James S, Maggioni AP, Wallentin L, Casadei B, Gale CP, Global Cardiovascular Outcomes Consortium and in collaboration with ACNAP, ACVC, EACVI, EAPC, EAPCI, EHRA, ESC Committee for Young CV Professionals, ESC Registry Committee, HFA, ESC Patient Forum and these Working Groups: aorta and peripheral vascular diseases, atherosclerosis and vascular biology, cardiac cellular electrophysiology, cardiovascular pharmacotherapy, cardiovascular regenerative and restorative medicine, cardiovascular surgery, cellular biology of the heart, e-cardiology, myocardial function, pulmonary circulation and right ventricular function and thrombosis
doi: 10.1093/eurheartj/ehae724
Cardiovascular Risk and Diseases
Bempedoic Acid Reduces the Risk of Major Adverse Cardiovascular Events Across Patient Subgroups
RECOMMENDED
Hypertension
Management of patients with hypertension and chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. On behalf of the European Society of Hypertension Working Group on Hypertension and the Kidney
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Blood Press
Halimi JM, Sarafidis P, Azizi M, Bilo G, Burkard T, Bursztyn M, Camafort M, Chapman N, Cottone S, de Backer T, Deinum J, Delmotte P, Dorobantu M, Doumas M, Dusing R, Duly-Bouhanick B, Fauvel JP, Fesler P, Gaciong Z, Gkaliagkousi E, Gordin D, Grassi G, Grassos C, Guerrot D, Huart J, Izzo R, Jaén Águila F, Járai Z, Kahan T, Kantola I, Kociánová E, Limbourg F, Lopez-Sublet M, Mallamaci F, Manolis A, Marketou M, Mayer G, Mazza A, MacIntyre I, Mourad JJ, Muiesan ML, Nasr E, Nilsson P, Oliveras A, Ormezzano O, Paixão-Dias V, Papadakis I, Papadopoulos D, Perl S, Polónia J, Pontremoli R, Pucci G, Robles NR, Rubin S, Ruilope LM, Rump LC, Saeed S, Sanidas E, Sarzani R, Schmieder R, Silhol F, Sokolovic S, Solbu M, Soucek M, Stergiou G, Sudano I, Tabbalat R, Tengiz I, Triantafyllidi H, Tsioufis K, Václavík J, van der Giet M, der Niepen PV, Veglio F, Venzin R, Viigimaa M, Weber T, Widimsky J, Wuerzner G, Zelveian P, Zebekakis P, Lueders S, Persu A, Kreutz R, Vogt L
doi: 10.1080/08037051.2024.2368800
Cardiovascular Risk and Diseases
Population-level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial
Diabetes Obes Metab
Nanna MG, Doan QV, Fabricatore A, Faurby M, Henry AD, Houshmand-Oeregaard AS, Levine A, Navar AM, Scassellati Sforzolini T, Toliver JC
doi: 10.1111/dom.16370